Loading stock…

IDEXX Laboratories, Inc. (IDXX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

IDEXX Laboratories, Inc.

IDXXMarket cap $40BPrice $506.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes diagnostic tests and equipment that veterinarians use to detect diseases in pets and livestock. Processes over 100 million pet tests annually, giving it unmatched data on animal health trends worldwide.

In Bastion Portfolios?

52W Return-20%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+9%6

Revenue Forecast

Rev CAGR (1y)+10%6

Rev CAGR (3y)+9%6

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+14%7

EPS Growth Y+2+12%7

EPS Growth Y+3+13%7

Quality

Margins

EBIT Margin32%9

Net Income Margin25%8

Free Cash Flow Margin28%9

Debt

Net Debt/EBITDA0.57

Efficiency

ROE74%10

ROA34%10

Earnings Stability88

GEAR+STRONG78

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)322

P/E Ratio (Forward 3y)272

P/BV24.81

EV Multiples

EV/EBITDA Fwd242

EV/EBIT Fwd273

Yield

Free Cash Flow Yield3.1%5

Dividend Yieldna–

Momentum

Short term

1 month return-3%6

3 month return-9%4

YTD return-25%2

Mid term

Price vs 52wHigh66%3

1 year return-20%3

Long term

3 year return+14%3

5 year return-18%3

Risk Shield

Price Risk

Beta0.85

Volatility32%6

Free Cash Flow

Free Cash Flow Margin28%9

Free Cash Flow Yield3.1%5

Quality

ROCE69%10

Earnings Stability88

Net Debt/EBITDA0.57

02Growth

Is it actually growing, and how fast?

IDXXIDEXX Laboratories

Revenue FY25$4.3B

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+14%7

EPS growth, FY27E+12%7

EPS growth, FY28E+13%7

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 9%/yr).

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 9%/yr over the last 3 years and is set to keep growing around 9%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK20 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return-9%4

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return-20%3

3-year return+14%3

5-year return-18%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-3%) and over three months (-9%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+14% over three years and -18% over five), behind 70% of the market.

It's down 20% over the past year, now 34% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-25%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on IDEXX Lab. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

IDXXIDEXX Laboratories

Revenue FY25$4.3B

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+14%7

EPS growth, FY27E+12%7

EPS growth, FY28E+13%7

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 9%/yr).

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 9%/yr over the last 3 years and is set to keep growing around 9%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK20 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return-9%4

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return-20%3

3-year return+14%3

5-year return-18%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-3%) and over three months (-9%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+14% over three years and -18% over five), behind 70% of the market.

It's down 20% over the past year, now 34% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-25%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on IDEXX Lab. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community